康华生物(300841.SZ):公司病毒性疫苗二车间通过药品GMP符合性检查并完成《药品生产许可证》变更
格隆汇5月30日丨康华生物(300841.SZ)公布,公司于近日获得了四川省药品监督管理局颁发的《药品GMP现场检查结果通知书》(编号:川2021061)和变更后的《药品生产许可证》。
同意该企业《药品生产许可证》原址改建车间:病毒性疫苗二车间,生产线:冻干人用狂犬病疫苗(人二倍体细胞)原液生产线,并通过药品GMP符合性检查,药品GMP符合性检查结果详见如下内容;其他内容不变。
公司病毒性疫苗二车间通过药品GMP符合性检查并完成《药品生产许可证》变更,有利于公司提升冻干人用狂犬病疫苗(人二倍体细胞)的产能,更好满足市场需求,对公司未来经营具有积极影响。
公司冻干人用狂犬病疫苗(人二倍体细胞)未来具体的生产、销售情况可能受到国家政策、市场环境等因素影响,具有不确定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.